Rohto Pharmaceutical Co.,Ltd.
RPHCF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $308,625 | $270,840 | $238,664 | $199,646 |
| % Growth | 14% | 13.5% | 19.5% | – |
| Cost of Goods Sold | $133,686 | $113,554 | $779 | $703 |
| Gross Profit | $174,939 | $157,286 | $1,017 | $937 |
| % Margin | 56.7% | 58.1% | 0.4% | 0.5% |
| R&D Expenses | $14,912 | $13,390 | $84 | $72 |
| G&A Expenses | $0 | $0 | -$45,786 | -$37,478 |
| SG&A Expenses | $57,506 | $54,219 | $681 | $636 |
| Sales & Mktg Exp. | $57,506 | $54,219 | $46,467 | $38,114 |
| Other Operating Expenses | $63,582 | $49,629 | $0 | $0 |
| Operating Expenses | $136,000 | $117,238 | $765 | $708 |
| Operating Income | $38,939 | $40,048 | $33,959 | $29,015 |
| % Margin | 12.6% | 14.8% | 14.2% | 14.5% |
| Other Income/Exp. Net | $3,392 | $1,470 | $331 | -$1,141 |
| Pre-Tax Income | $42,331 | $41,518 | $34,290 | $27,874 |
| Tax Expense | $11,379 | $10,123 | $7,860 | $6,686 |
| Net Income | $31,006 | $30,936 | $26,377 | $21,127 |
| % Margin | 10% | 11.4% | 11.1% | 10.6% |
| EPS | 136.11 | 135.6 | 115.62 | 92.61 |
| % Growth | 0.4% | 17.3% | 24.8% | – |
| EPS Diluted | 135.44 | 135.21 | 115.29 | 92.34 |
| Weighted Avg Shares Out | 228 | 228 | 228 | 228 |
| Weighted Avg Shares Out Dil | 229 | 229 | 229 | 229 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,223 | $1,523 | $962 | $368 |
| Interest Expense | $949 | $196 | $247 | $248 |
| Depreciation & Amortization | $13,143 | $8,687 | $7,801 | $7,689 |
| EBITDA | $56,423 | $50,401 | $42,338 | $35,811 |
| % Margin | 18.3% | 18.6% | 17.7% | 17.9% |